Drugs / BL-M02D1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05385692 | Jun 2022 → Dec 2025 overdue | digestive system cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05339685 | May 2022 → Dec 2025 overdue | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05949619 | Sep 2023 → Dec 2025 overdue | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-10 | Sichuan Biokin Pharmaceutical Co., Ltd. | Results 四川百利天恒药业股份有限公司自愿披露关于7项研究成果入选2023年第114届美国癌症研究协会（AACR）年会展示的公告 cninfo.com.cn ↗
报告标题： BL-M02D1, a novel Trop2 -targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-10 | Sichuan Biokin Pharmaceutical Co., Ltd. | 四川百利天恒药业股份有限公司自愿披露关于7项研究成果入选2023年第114届美国癌症研究协会（AACR）年会展示的公告 cninfo.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-M02D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05339685 ↗ |
| Route | Intravenous | “Administration by intravenous infusion” NCT05339685 ↗ |